ESR1 and breast carcinoma: Unfortunately, a major challenge involves a large proportion of breast cancer patients developing resistance to these treatments (50% of ERα+/PR+ breast cancer, which comprises 70–80% of all breast cancers, inevitably recur) [21,34,35].